🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524134-26-00
Completed Phase I

Effect of NBI-921355 on corticospinal excitability in healthy participants

2025-524134-26-00 · tracked via the Priya Life Science EU tracker
Sponsor
Neurocrine Biosciences Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
29/04/2026
Enrollment target
24
Sites
Netherlands

Condition studied

Epilepsy

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524134-26-00 on CTIS ↗ ← All trials in the EU